Compugroup Medical Ag Stock Revenue
| 0MSD Stock | 14.03 0.01 0.07% |
CompuGroup Medical AG fundamentals help investors to digest information that contributes to CompuGroup Medical's financial success or failures. It also enables traders to predict the movement of CompuGroup Stock. The fundamental analysis module provides a way to measure CompuGroup Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CompuGroup Medical stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.2 B | 622.4 M |
CompuGroup | Revenue |
CompuGroup Medical AG Company Revenue Analysis
CompuGroup Medical's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current CompuGroup Medical Revenue | 1.19 B |
Most of CompuGroup Medical's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CompuGroup Medical AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of CompuGroup
Projected quarterly revenue analysis of CompuGroup Medical provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of CompuGroup Medical match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in CompuGroup Medical's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
CompuGroup Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, CompuGroup Medical AG reported 1.19 B of revenue. This is 70.86% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The revenue for all United Kingdom stocks is 87.41% higher than that of the company.
CompuGroup Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CompuGroup Medical's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CompuGroup Medical could also be used in its relative valuation, which is a method of valuing CompuGroup Medical by comparing valuation metrics of similar companies.CompuGroup Medical is currently under evaluation in revenue category among its peers.
CompuGroup Fundamentals
| Return On Equity | 0.0379 | |||
| Return On Asset | 0.0305 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.5 B | |||
| Shares Outstanding | 49.56 M | |||
| Shares Owned By Insiders | 50.35 % | |||
| Shares Owned By Institutions | 23.26 % | |||
| Price To Sales | 1.69 X | |||
| Revenue | 1.19 B | |||
| Gross Profit | 411.71 M | |||
| EBITDA | 215.84 M | |||
| Net Income | 46.87 M | |||
| Total Debt | 766.94 M | |||
| Book Value Per Share | 12.26 X | |||
| Cash Flow From Operations | 179.53 M | |||
| Earnings Per Share | 1.44 X | |||
| Number Of Employees | 8.41 K | |||
| Beta | 0.86 | |||
| Market Capitalization | 2.01 B | |||
| Total Asset | 1.9 B | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 1.9 B | |||
| Last Dividend Paid | 1.0 |
About CompuGroup Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CompuGroup Medical AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CompuGroup Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CompuGroup Medical AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CompuGroup Stock Analysis
When running CompuGroup Medical's price analysis, check to measure CompuGroup Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CompuGroup Medical is operating at the current time. Most of CompuGroup Medical's value examination focuses on studying past and present price action to predict the probability of CompuGroup Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CompuGroup Medical's price. Additionally, you may evaluate how the addition of CompuGroup Medical to your portfolios can decrease your overall portfolio volatility.